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Background:Healthcare resource utilization is an understudied aspect of vascular surgery. Initial cost of a given procedure
is not an accurate reflection of resource utilization because it does not account for procedural durability and efficacy.
Herein we describe an amortized cost model that accounts for procedural costs, durability, and re-intervention costs.
Methods:A cost model was developed using patency data endpoints and total hospital costs (direct and indirect) associated
with an inital revascularization and subsequent re-interventions. This model was applied to a retrospective database of
femoropopliteal reconstructions. One hundred and eighty-three open cases were compared with 198 endovascular cases;
and the endpoints of initial cost, amortized cost at 12 months, and assisted patency were examined.
Results: The open and endovascular cases were not statistically different with respect to indication, patient co-morbid
profiles, or post-procedural pharmacotherapy. Primary assisted patency was better in the open revascularization group at
12months (78% versus 66%, P< .01). There was a statistically significant higher initial cost for open reconstruction when
compared with endovascular ($12,389  $408 versus $6,739  $206, P < .001). However, at 12 months post-
procedure, the initial cost benefit was lost for endovascular patients ($229 $106 versus $185 $124, P .71). There
was, however, a trend for endovascular cost savings in claudicants, though this did not reach significance ($259  $189
versus $86  $52, P  .31). For patients with critical limb ischemia, renal dysfunction, and end stage renal disease, the
trend favored open surgery.
Conclusions:An amortized cost model provides insight into the healthcare resource utilization associated with a particular
revascularization and assistive procedures. The initial cost savings of endovascular therapies are not sustained over time.
Cost-savings trends were noted, however, longer follow-up is required to see if these will reach statistical significance.
(J Vasc Surg 2008;48:1489-96.)Payment for the treatment of peripheral arterial disease
(PAD) results in a significant cost to the healthcare system.
In 2007, the United States (US) federal government spent
151 billion dollars in direct and indirect costs for the
treatment of the eight to 12 million Americans with PAD.
It is anticipated that this figure will continue to grow as
baby boomers age and as hospitals and doctors expand their
vascular practice in order to realize a population of patients
as a new source of revenue.1
In the overall picture of healthcare spending, more than
500 billion US dollars are earmarked for Medicare and
Medicaid payments this year, and this figure is expected to
increase by 31% over the next five years. If costs continue to
grow as projected, the United States federal government
will spend approximately 20% of its gross domestic product
on healthcare by 2050.2
In facing this looming crisis in healthcare reimbursement,
responsible providers will need to know the true clinical ben-
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Vascular providers have available an ever-increasing array of
new and potentially expensive modalities to treat PAD. De-
creased healthcare resource utilization and lower procedural
cost is often cited as rationale for technology adoption. Many
of these new modalities compete with traditional open surgi-
cal procedures, and have not been fully evaluated for either
clinical efficacy or cost effectiveness. Furthermore, the con-
temporary discussion about the cost of treatment modalities
has frequently only taken into account the initial cost of the
treatment rendered, which is flawed and myopic. There must
be accounting for procedural success, procedural durability,
and patient longevity, all of which are important factors in
determining clinical and cost efficacy.
With this in mind, we reviewed our contemporary expe-
rience with open and endovascular therapy in the treatment of
femoropopliteal occlusive disease. The primary aim of this
study was to develop a simple cost efficacy framework that can
be used to study the economic impact of any vascular recon-
struction, taking into account the varying initial cost, patency
and reintervention. The secondary aim was to utilize this new
model to determine if the initial cost savings of endovascular
therapy is sustained over time.
METHODS
Cost model. An amortized cost model was developed
to examine the cost efficacy characteristics of a given revas-
cularization procedure. To determine cost at any time, we
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maintain patency. This takes into account the initial cost
and the cost of all subsequent interventions. This is then
divided by time in days to give the cost per day of patency.
When an intervention failed patency, the cost per day of
patency remains static throughout the remaining time pe-
riod of the study.
Cost per day of patency is expressed at any given time
interval (t) as follows:
Cost(t) 
t → pa
lim 
i0
t
Cost(i)
t
(1)
Where pa  maximum number of days of assisted patency
and Cost(i)  total hospital costs (direct and indirect) at
time interval i days from index procedure (t 0). With this
cost model, the cost per day of patency was assessed at any
given time interval from the index procedure. Hypothetical
situations are illustrated in the cost efficacy curves of Fig 1.
The figure depicts a series of patients undergoing revascu-
larization. Patient A undergoes a successful revasculariza-
tion, without the need for subsequent reintervention
throughout the follow-up time period. Patient B requires a
secondary procedure to maintain patency (primary assisted
or secondary), and subsequently maintains patency. Finally,
Patient C fails patency and an assistive procedure is not
undertaken. Of note, total hospital costs were accounted
for at each time point. If a patient suffered a complication or
adverse event from a given procedure, the financial burden
of that event was included in the model (costs and indirect
costs associated with treatment of that complication).
Cross-over to the other mode of therapy was considered a
failure to maintain patency.
For the purpose of this study, total cost (direct and
Fig 1. Hypothetical cost efficacy curves for the following revas-
cularization scenarios: A (blue) – Successful initial revasculariza-
tion without failure of patency or reintervention, B (green) –
Re-intervention to maintain patency, C (red) – Failure of patency
without reintrevention.indirect cost) for the particular encounter was used tocalculate the amortized cost. This cost data was obtained
from hospital billing records. If a patient was admitted to
the hospital for a non-lower extremity problem, only those
costs associated with the appropriate diagnosis-related
group (DRG) were used. Costs associated with adverse
outcomes after a particular revascularization were also in-
cluded for the total encounter cost calculation. Cost data
was available for all patient encounters in this study. If the
patient underwent a major amputation ipsilateral to the
index revascularization, this was included in the cost anal-
ysis. Cost of postoperative rehabilitation, nursing home, or
lost days of work was not included in this analysis.
Patient selection and data collection. In order to
examine the use of the aforementioned model, a cohort of
patients undergoing lower extremity revascularization was
examined. The study was approved by the University and
Medical Center Institutional Review Board of East Caro-
lina University. From July 2003 to July 2006, all patients
who had undergone open or endovascular treatments of
femoropopliteal arterial circulation were identified in a
retrospective computerized database. Patients were identi-
fied using the hospitals billing database using appropriate
Common Procedural Terminolgy (CPT) codes. The deci-
sion to use open bypass or endovascular revascularization
was based on clinical evaluation, anatomical factors, and the
attending surgeon’s preference.
Preoperative, procedural, andoutcome variableswere col-
lected from the computerized patient care records. Basic de-
mographic data were recorded, omitting patient identifying
information.The indication for revascularizationwas classified
by the criteria of Rutherford et al., and critical limb ischemia
(CLI) was defined as Rutherford category 3.3
Patient comorbidities were defined as:
● Diabetes mellitus: medical treatment of diabetes;
● Hypertension: medical treatement of hypertension;
● Hyperlipidemia: medical treatment of dyslipidemia or
total cholesterol  200 mg/dl;
● Tobacco use: recorded as both lifetime tobacco use
and current use;
● Coronary disease: medical therapy for coronary vascu-
lar disease or prior coronary revascularizaton;
● Renal insufficiency: serum creatinine 1.5 mg/dl
● End stage renal disease: renal failure requiring chronic
renal replacement therapy.
Perioperative medical management was noted with re-
spect to the following agents: Aspirin, Clopidogrel (Plavix,
Sanofi-Aventis, Bridgewater, NJ), Warfarin (Coumadin,
Bristol-Myers Squibb, Princeton, NJ), lipid lowering
therapy.
Anatomic and morphologic characteristics were ob-
tained by review of the archived images from the individual
cases. Calibrated angiography was used to determine lesion
lengths and infrapopliteal run-off was recorded. These data
were used to assign the target lesion with a TransAtlantic
Inter-Society Concensus (TASC II) classification.4
Specific data points were collected based on the type of
revascularizaton performed. Type of graft conduit and tar-
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modality (ie, angioplasty, stenting, atherectomy or cryo-
plasty) was documented for those undergoing endovascular
revascularization. Several data points that did not impact
the cost model were omitted from this manuscript for the
sake of simplicity and brevity.
Long-term end points. The primary endpoint of this
study was cost per patient day of patency 12 months
following the index procedure. The time interval of 12
months was chosen because the fraction of patients in each
group available for follow-up was equal at that time point.
At later times, fewer of the endovascular patients were
available for follow-up, owing to the fact that an increasing
number of the endovascular cases took place in the latter
half of the study. For a given patient, the cost model was
used to generate the cost per day of patency at 1 year.
Primary patency and primary-assisted patency were the
secondary end points in this study. Patency was determined
by the guidelines of Rutherford et al. and used routine
physiologic examinations in those without a palpable pulse
including duplex ultrasonography, ankle brachial index
(ABI), and pulse volume recordings (PVR).3 Deterioration
in clinical status or hemodynamics prompted further imag-
ing. Duplex ultrasonography was used to follow all patients
with a bypass graft and those with a stent. A peak systolic
velocity ratio  2.0 prompted further imaging in these
patients. Total follow-up time was recorded for each pa-
tient as well as the time to failure of primary, primary-
assisted, and secondary patency.
Statistical analysis. The software code for the cost
model was developed using Microsoft Visual Basic and
employed a Microsoft Excel spreadsheet to input the data
and record the output of the model (Microsoft Corp.,
Redmond,Wash). A developmental version of this software
code is freely available under the terms of the GNUGeneral
Public License.5 The average amortized cost per day of
patency was compared between open and endovascular
therapy groups. Results were analyzed using the Student t
test and are presented as mean standard error. A P .05
was considered significant for all statistical analyses. Kaplan-
Meyer life tables were created and patency was examined
using log-rank analysis. Multivariate logistic regression was
used to analyze the categorical variables associated with
early failure of primary patency (30 days). Variables with
a P  .10 were considered candidate variables for this
analysis. These data were analyzed using SAS 9.1 software
(SAS institute Inc, Cary, NC).
RESULTS
Over a three-year period, a total of 381 femoropopliteal
segments were treated in 359 patients. There were a total of
183 femoropopliteal segments treated with open revascu-
larization and 198 treated with endovascular therapy. Both
treatment groups were well matched with no significant
difference in clinical variables including: Rutherford cate-
gory, age, gender, diabetes, hypertension, end stage renal
disease requiring dialysis, tobacco, run-off, and post-
operative pharmacotherapy (Table I).In the open group, 165 of 183 bypasses (90%) were
above-knee grafts using prosthetic conduit. Of the 198
endovascular cases, 75 (38%) were TransAtlantic Inter-
Society Consensus (TASC) II classification C or D cases.
Subintimal angioplasty was routinely utilized in the treat-
ment of TASC D cases. A luminal re-entry device was used
in only 5 cases (7% of TASCC or D cases). Stents were used
in 42 (21%) of cases owing to a suboptimal result with
standard angioplasty (30% residual stenosis or flow-
limiting dissection); and atherectomy (mechanical or laser)
was used in a total of 26 (13%) of cases.
Durability data demonstrated that primary assisted pa-
tency (all indications) at twelve months was 77%  0.03%
for the open group and 65%  0.04% for the endovascular
group (P .01). Primary assisted patency for patients with
claudication at twelve months was 93%  0.03% in the
open group versus 80% 0.04% in the endovascular group
(P .01, Fig 2). Primary assisted patency for patients with
critical limb ischemia at twelve months was 66% 0.05% in
the open group and 54%  0.05% in the endovascular
group (P  .01, Fig 3).
Initial cost of open therapy was significantly higher in all
subgroups (Table II). Using the model of amortized cost
described above, the cost per day of patency was calculated at
one year. A graphical representation of the cost model is
shown in Figs 3 and 4. Despite the difference in initial cost,
our model showed no statistically significant difference in
amortized cost at one year between open and endovascular
groups regardless of indication. For all indications, the amor-
tized cost per day of patency at 12 months was $229 $106
for open cases and $185 $124 for endovascular cases (P
.71, Table III). Claudicants treated by simple angioplasty
showed the lowest cost per day of patency ($26  $14)
although this did not reach statistical significance when
compared with open therapy in such patients (Fig 5).
The driving forces of this cost model are the initial proce-
Table I. Demographic, clinical and anatomical
characteristics of open and endovascular cases of
femoropopliteal evascularization
Open
(n  183)
Endovascular
(n  198) P
Age (years  SE) 63.9  0.9 66.0  0.9 .10
Male 63.1% 57.9% .29
Critical limb ischemia 55.7% 43.4% .10
Diabetes 48.1% 50.0% .70
ESRD 13.1% 9.1% .80
Creatinine  1.5 mg/dl 14.8% 15.6% .80
Runoff  2 vessels 49.1% 53.0% .45
TASC C or D N/A 37.7% N/A
Lesion length  10 cm N/A 21.3% N/A
Stent N/A 21.3% N/A
Prosthetic graft 98% N/A N/A
Above-knee graft 90% N/A N/A
12-month follow-up 86.3% 79.8% .10
Failed, no-reintervention 28.7% 24.6% .35
ESRD, end stage renal disease; TASC, Trans-Atlantic Inter-Society
Consensus.dural cost, the costs of all assistive procedures, and the dura-
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amortized portion of the model are shown in Table IV.
Failures, especially those that were not subjected to reinter-
vention, are a very significant part of this construct. A high rate
of failures and lack of re-intervention is especially evident in
both the open and endovascular groups with critical limb
Fig 2. Kaplan-Meyer curve demonstrating probability of primary-
assisted patency from time of index procedure in both open (red)
and endovascular (blue) cases for patients with claudication
(P  .01).
Fig 3. Kaplan-Meyer curve demonstrating probability of primary-
assisted patency from time of index procedure in both open (red)
and endovascular (blue) cases for patients with critical limb isch-
emia (P  .01).ischemia. Exact reasons for lack of re-intervention are difficultto determine retrospectively, but are in general attributable to
sub-optimal anatomic or patient co-morbid conditions, in
which reintervention is thought to be just as likely to fail.
Failure without re-intervention resulted in a significantly
higher amortized cost compared with failure with reinterven-
tion in the endovascular group ($551  $184 versus $34 
$4, P  .01, Table III), and a trend towards a similar higher
cost in the open group ($418  $154 versus $157  $122,
P .23, Table III).
Utilizing the model, subgroup analysis was undertaken
to identify risk factors in which one therapy was more cost
effective. Patients with critical limb ischemia, end stage
renal disease requiring dialysis, renal insufficiency (creati-
nine  1.5 mg/dL), and congestive heart failure showed a
trend towards open revascularization being more costeffec-
tive; however, this did not reach statistical significance.
Because early failures have a significant impact on this
Table II. Initial cost of open and endovascular
femoropopliteal revascularization stratified by indication
Open – Initial
cost ($  SE)
Endovascular –
Initial cost ($  SE) P
All indications 12,389  408 6,739  260 .001
Critical limb
ischemia 13,277  598 7,176  309 .001
Claudicants 11,042  468 6,287  415 .001
Diabetes 12,233  530 6,714  342 .001
Creatinine 1.5
mg/dl 14,922  1510 7,602  844 .001
ESRD 12,562  613 7,236  586 .001
CHF 12,414  761 7,012  568 .001
Runoff 2 vessels 13,425  712 7,262  344 .001
Stent placement 12,389  408 9,453  705 .01
TASC C/D 12,389  408 7,540  492 .001
CHF, congestive heart failure; ESRD, end stage renal failure, TASC, Trans-
Atlantic Inter-Society Consensus.
Fig 4. Cost efficacy curves in patients undergoing revasculariza-
tion via both open (red) and endovascular (blue) techniques for
patients with claudication.model, a multivariate analysis was undertaken to indentify
Atlan
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disease (ESRD) requiring dialysis was an independent risk
factor for early failure in patients with critical limb ischemia
for both open and endovascular therapy. (odds ratio
[OR] 3.48, P .048). No other variable was a significant
correlate of early failure.
DISCUSSION
Healthcare cost utilization is a poorly understood as-
pect of vascular surgery. When two different modalities can
be used to treat the same disease process, there is an easy
opportunity for comparison, including total longitudinal
cost and durability. In the current environment, it is impor-
tant to have an understanding of these competing modali-
ties. There exists a considerable amount of controversy over
the use of open and endovascular procedures, principally
because of the diversity of vascular care providers. Histori-
cally, the lower initial costs and less invasive nature of
Table III. Cost per patient-day of patency at 12 months f
Open – 12 months
($/patient-day patency 
All indications 229  106
Critical limb ischemia 210  80
Claudicants 259  189
Diabetes 402  208
Creatinine 1.5 mg/dl 129  51
ESRD 248  149
CHF 76  15
Runoff 2 vessels 439  213
Stent placement 229  106
TASC C/D 229  106
Failed, yes reintervention 157  122
Failed, no reintervention 418  154
CHF, congestive heart failure; ESRD, end stage renal failure, TASC, Trans-
Fig 5. Cost efficacy curves in patients undergoing revasculariza-
tion via both open (red) and endovascular (blue) techniques for
patients with critical limb ischemia.percutaneous endovascular procedures have won out overthe more expensive but potentially more durable open
procedures.
This study provides a well-matched group of patients
treated for femoropopliteal occlusive disease. While this
study is limited by its retrospective nature, moderate sample
size and the inherent treatment biases that exist in any
practice, it follows the literature in that, with respect to
complex femoropopliteal disease, the patency of open re-
vascularization is superior to that of endovascular. The data
presented here represent a significant number of such cases
(37.7% TASC C or D). The initial cost of open revascular-
ization is also significantly higher than endovascular ther-
apy, as has also been described.6,7
Multiple attempts have been made to develop cost
models. Our model of cost per patient-day of patency gives
a surrogate measure of a cost benefit ratio by adding in
often unconsidered factors such as overall patency and
reintervention rates. This cost efficacy model becomes
static during the follow-up period once a particular inter-
vention looses assisted patency. Through this mechanism,
revascularization failures, especially early ones, weigh
heavily. The inclusion of total hospital costs associated with
the procedure, including those associated with adverse
events, accounts for the economic impact of procedural-
associated morbidity.
The relationship between procedural cost and clinical
success is often indirect. For instance, a 2005 study dem-
onstrated that endovascular procedural costs were signifi-
cantly higher in more complex cases compared with open
surgery, and that these increased costs did not necessarily
translate to an improved clinical outcome.6 The authors
conclude that when the clinical efficacy of procedures over-
lap, percutaneous strategies should be employed based on
these economic factors. This statement holds true only if
the subsequent economic burden for reintervention either
favors endovascular treatment or is at least equivalent to
that of open surgery. Once this relationship between cost
and durability is realized, it is relatively simple to derive
both procedural cost and efficacy targets for a given modal-
index procedure, stratified by indication
Endovascular – 12 months
($/patient-day patency  SE) P
185  124 .71
359  143 .33
86  52 .31
284  119 .62
383  305 .44
495  226 .39
355  170 .17
304  112 .56
150  98 .70
228  138 .98
34  4 .28
551  184 .58
tic Inter-Society Consensus.rom
SE)ity and patient co-morbidity profile.8
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model and to apply it to a sample data set. Similar models
have been described in the literature, however, our model is
unique in that we described an amortized cost per day of
patency associated with a single index procedure.6,9 Cross-
over to another mode of treatment was considered a failure,
and the revascularization cost was held static at that time
point. Therefore, documented patency and procedural du-
rability become the main driving forces for economic suc-
cess. Using endpoints such as freedom from re-operation or
limb salvage are other possibilities, and likely the informa-
tion obtained by applying thesemodels would differ. This is
because these soft endpoints would likely improve the
durability profile of endovascular therapy, more so than
open therapy. The societal definition of primary-assisted
patency was utilized as our efficacy endpoint so that these
data would be comparable to other contemporary series in
Table IV. Number of assistive procedures, total cost of as
undergoing reintervention listed by number of months fro
CLI) and modality (open or endovascular)
Time
(months)
Claudicants – open
(n  81)
Claudicants –
endovascular (n 
Proc.
(n)
Cost
(k$)
Failed
(n)
Proc.
(n)
Cost
(k$)
1 1 16.6 1 1 27.9
2 0 0 0 0 0
3 0 0 1 1 6.8
4 0 0 2 0 0
5 1 16.4 0 1 4.9
6 0 0 0 1 7.4
7 0 0 0 1 19.5
8 1 5.1 0 1 4.7
9 2 26.1 2 1 7.2
10 0 0 1 0 0
11 0 0 0 0 0
12 0 0 0 0 0
CLI, critical limb ischemia; Proc, procedures.
Table V. Multivariate analysis for variables associated
with early failure ( 30 days)
Odds ratio
95% Confidence
limits P
Patient factors
Age 80 years 1.738 0.411-7.359 .667
Diabetes 1.390 0.402-4.809 .453
Hypertension 0.455 0.058-3.553 .452
Hyperlipidemia 0.375 0.051-2.732 .332
ESRD 3.848 1.012-14.633 .040
CHF 2.842 0.861-9.380 .086
Pharmacology
Statin 1.575 0.181-13.733 .681
Coumadin 1.261 0.275-5.771 .765
Anatomic
Runoff 2 vessels 0.560 0.411-7.359 .355
CHF, congestive heart failure; ESRD, end stage renal failure.the vascular surgery literature.The conclusions from this analysis are based on a rela-
tively small group of patients, and therefore the risk of
statistical error is significant. The authors’ intent is merely
to provide an example application of this cost efficacy
framework. The decision to compare open with endovas-
cular revascularization was based on the observation that
there is an increasing trend towards its acceptance as the
first-line therapy for arterial occlusive disease.10-12 These
data could readily be stratified by other factors and patient
co-morbidities, not just treatment modality. For example,
cost per day of patency could be compared between diabet-
ics and nondiabeteics. Furthermore, the model could easily
be adapted to examine other cost efficacy scenarios such as
limb salvage (cost per day of limb salvage), carotid revascu-
larization (cost per day of stroke-free survival), coronary
revascularization (cost per day of coronary-related event
free survival), and aortic aneurysm repair (cost per day of
aneurysm-related event free survival).
Interestingly, despite a nearly two-fold difference in
initial cost, the cost savings of endovascular therapy is not
carried out over time. The loss of the cost benefit of
endovascular therapy lies in its lower patency rates and need
for subsequent reintervention. This is evident particularly
in the critical limb ischemia cohort where at one year,
endovascular therapy is trending to become the more ex-
pensive modality. The 11% difference in patency at one year
and the early failures of patency (30 days) are the major
influences on this high cost. This economic benefit to open
revascularization in patients with critical limb ischemia has
been described before for patients with complex arterial
occlusive disease.13
Claudicants treated by endovascular therapy have a
noticeable trend toward cost savings compared with open
therapy, despite a 14% differential in patency at one year. In
particular, those treated by simple angioplasty with no
e procedures and number of failed revascularizations not
dex procedure, stratified by indication (Claudicant or
CLI – open (n  102)
CLI – endovascular
(n  86)
d Proc.
(n)
Cost
(k$)
Failed
(n)
Proc.
(n)
Cost
(k$)
Failed
(n)
3 35.8 10 0 0 18
0 0 4 0 0 9
0 0 2 0 0 3
2 24.3 4 1 13.1 2
0 0 5 1 13.6 1
2 20.5 1 1 8.9 1
1 6.7 0 1 7.2 1
1 7.6 2 0 0 1
1 14.2 1 1 7.7 0
0 0 0 0 0 1
0 0 0 0 0 0
0 0 1 0 0 0sistiv
m in
112)
Faile
(n)
4
3
3
1
0
1
1
0
1
2
0
0other adjunctive interventions showed the greatest savings.
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failures in the endovascular group and the often high
expense of reintervention in the open group. The improved
cost benefit ratio of angioplasty compared with bypass in
the treatment of claudicants has been noted in a recent
Markov decision model-based study.14 Of course, exercise
therapy is an integral component in the treatment of inter-
mittent claudication, and may possess a positive cost effi-
cacy profile.15 Our current database is restricted to open
and endovascular revascularizations, and therefore we are
unable to comment on the application of this cost model to
exercise therapy.
The cost per day of patency of open therapy appears to
favor those with critical limb ischemia, ESRD, renal insuf-
ficiency and heart failure. Caution must be taken when
considering these results because of low patient numbers
and high error margins. The trend favoring open therapy
relates to the very high early failure rates seen with endo-
vascular reconstructions in these often poor candidates.
ESRD offers a complex problem as it has a high early failure
rate in both open and endovascular therapy in patients with
critical limb ischemia. Based on our results, it is difficult to
recommend any therapy based on our cost analysis. The
poor cost benefit ratio encountered when treating ESRD
patients with critical limb ischemia is prohibitive in all but a
select few, and argues for conservative therapy and early
primary amputation. These strikingly inferior outcomes
have been well documented in the literature.16-18
The primary flaw of this study lies in the sample data-
base used to illustrate the model. The data are from a single
institution, and therefore demonstrate biases inherit to any
individual practice pattern. Furthermore, as mentioned
above, there was a heterogenous follow-up between the
two groups. Because of an increasing percentage of endo-
vascular cases in the latter half of the study, we were forced
to terminate the cost calculations at 12 months. This is
arguably a relatively short period of time, and further
follow-up of this cohort will be required to see if the trends
noted above will reach statistical significance. With respect
to the cost model, we have not accounted for larger societal
costs, such as rehabilitation, nursing home stays, and lost
productivity associated with longer hospital stays. While
this could be accounted for with some modification, we
elected to not address this factor. The goal of this study was
to develop a simple cost model, which utilizes standard
patency and follow-up data in conjunction with readily
available institutional financial data.
CONCLUSION
A cost efficacy model was developed that uses standard
patency data and information readily available from any
healthcare system’s financial database. This model was ap-
plied to a retrospective femoropopliteal revascularization
database in order to demonstrate its use and feasibility. In
this model, procedural durability and reintervention costs
appear to be significant factors when determining overall
cost to the healthcare system. Models for healthcare utili-
zation in vascular surgery must to take into account initialcost, patency, and reintervention rate if a sustainable
growth model of healthcare is to be developed.
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